China Takes A Bigger Role In The World Pharma Stage
COVID-19’s Impact On R&D And Novel Drug Launches Wanes
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.
You may also be interested in...
While many of his peers elbowed each other to leap into oncology, James Xue decided to focus on rare diseases such as Hunter’s Syndrome. Now, 10 years after founding CANbridge, the CEO sat down for an audio interview with Scrip to offer his views on a flurry of key issues impacting orphan drug development in potentially the world's largest pharma market.
While two Chinese companies gained domestic approvals for their recombinant protein and adenovirus-based COVID-19 shots as heterologous boosters in February, these currently only account for roughly 21% of all booster shots, showing the continued predominance of inactivated virus-based technology in the country.
Four Chinese RNA technology developers, including Rona Therapeutics and METiS Pharmaceuticals, have bagged the most proceeds in recent financing rounds in the country backed by venture capital and private equity funds.